Paper Details

  1. Home
  2. Paper Details

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial.

Author: , Andia-BiraroIrene, ChambaNyasatu, CritchleyJulia A, HillPhilip C, KibirigeDavis, KilonzoKajiru, KyazzeAndrew Peter, LaizerSweetness, MagombolaDavid, MremaLucy, MwayulaIssakwisa Habakkuk, NinsiimaSandra, NtinginyaNyanda Elias, OlomiWillyhelmina, RomeoRenee, SabiIssa, SharplesKatrina, Te BrakeLindsey, van CrevelReinout, van de MaatJosephine

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This trial will examine the efficacy and safety of a 12-week course of rifapentine and isoniazid (3HP) as a preventative therapy against tuberculosis (TB) in people with diabetes mellitus (DM) who have latent TB infection (LTBI).
Paper Details　
Original Abstract of the Article :
Diabetes mellitus (DM) increases the risk of tuberculosis (TB) and will hamper global TB control due to the dramatic rise in type 2 DM in TB-endemic settings. In this trial, we will examine the efficacy and safety of TB preventive therapy against the development of TB disease in people with DM who h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186476/

データ提供：米国国立医学図書館（NLM）

Combating the Double Threat: Diabetes and Tuberculosis

In the ever-shifting sands of [Infectious Diseases], we encounter a formidable duo: diabetes mellitus (DM) and tuberculosis (TB). This deadly combination poses a significant challenge, especially in regions where both diseases are prevalent. This study explores the potential of a powerful preventative therapy, rifapentine and isoniazid (3HP), to protect individuals with DM from the threat of TB. They are conducting a randomized controlled trial to assess the efficacy and safety of 3HP in individuals with DM who have latent TB infection (LTBI). The results of this trial will be crucial for strengthening global TB control, as diabetes is on the rise in TB-endemic regions.

A Beacon of Hope for Diabetes and Tuberculosis

This study presents a promising avenue for tackling the intertwined threat of diabetes and tuberculosis. Think of it as a shield against a double-edged sword. By targeting latent TB infection in individuals with DM, this preventative therapy could significantly reduce the risk of developing active TB disease. The trial will provide valuable data on the effectiveness and safety of 3HP, paving the way for improved TB control strategies in a world where both diabetes and TB are on the rise.

Living with Diabetes and TB: A Guide for Prevention

This research highlights the importance of preventative measures for individuals with diabetes, who are at increased risk of tuberculosis. It underscores the need for early diagnosis and treatment of latent TB infection, a crucial step in preventing the development of active TB. It's like a compass guiding us through the complex landscape of co-existing diseases, helping us find the path to better health.

Dr.Camel's Conclusion

This research investigates the potential of rifapentine and isoniazid (3HP) as a preventative therapy for tuberculosis in individuals with diabetes. The trial will provide valuable insights into the efficacy and safety of this treatment, potentially contributing to improved TB control strategies, particularly in TB-endemic regions.

Date :
  1. Date Completed 2022-06-14
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35689272

DOI: Digital Object Identifier

PMC9186476

Related Literature

Article Analysis
・Effects of rifamycin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.